Drug Delivery Systems Marketing Regulation 
XTalks
OCTOBER 27, 2021
Genentech’s ocular implant drug delivery system for treatment of macular degeneration has received approval from the US Food and Drug Administration (FDA). Susvimo delivers ranibizumab via a port delivery system into a surgically placed implant in the eye, allowing for continuous delivery of the drug.
Pharmaceutical Technology
OCTOBER 26, 2022
Nano-based delivery systems are on the rise, as they enable manufacturers to deliver therapeutic agents to specific targeted tissue in a more controlled manner. Data indicates that the global nanopharmaceutical drugs market size reached USD 53.85 Billion in 2021 and is expected to reach USD 102.4 Billion in 2030.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
MAY 30, 2023
The healthcare industry has one of the heaviest environmental footprints, and manufacturers are increasingly faced with regulations to make more sustainable products,” said Mohammad H. The Global ECG Patch Market The global ECG patch and holter monitor market , estimated to be around $13 billion and projected to grow at a 17.5
Pharmaceutical Technology
FEBRUARY 3, 2023
In 2021, 72% of newly approved drugs were small molecules, and almost 50% of new drugs approved were OSD. While the industry is seeing advances in alternative drug delivery systems, oral solid doses, such as pills, capsules and soft gels, remain at the forefront of the industry.
XTalks
AUGUST 24, 2022
By the end of this year, the EPA plans to propose an air pollution regulation to address EtO emissions at commercial sterilizers and to protect public health. XTALKS WEBINAR: ISO 11608: Best Practices to De-Risk & Shorten Time to Market for Wearable Injectors.
Pharmaceutical Technology
APRIL 24, 2023
Conde says the use of nanoparticle delivery for gene therapies has become more common over recent years. Nanoparticles can be tailored to target specific cells or tissues, release gene therapies in a regulated manner, reduce toxicity, and increase stability,” he added. Please check your email to download the Report.
FDA Law Blog
SEPTEMBER 19, 2023
The six-page statement explains that “Brand drug manufacturers may be harming generic competition through the improper listing of patents in the. But it is not always clear which types of patents are eligible for listing in the Orange Book.
Expert insights. Personalized for you.
104 
Let's personalize your content